Quest for the right Drug
ספקטרצף 400 מ"ג SPECTRACEF 400 MG (CEFDITOREN AS PIVOXIL)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליות מצופות פילם : FILM COATED TABLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Posology : מינונים
4.2 Posology and method of administration The recommended dosage depends on the severity of the infection, the basal condition of the patient and the potential micro-organisms involved. Posology Adults and adolescents (over 12 years) • Acute pharyngo-tonsillitis: 200 mg cefditoren every 12 hours for 10 days. • Acute maxillary sinusitis: 200 mg cefditoren every 12 hours for 10 days. • Acute exacerbations of chronic bronchitis: 200 mg cefditoren every 12 hours for 5 days. • Community-acquired pneumonia: - In mild cases: 200 mg cefditoren every 12 hours for 14 days. - In moderate cases: 400 mg cefditoren every 12 hours for 14 days. • Uncomplicated skin and skin structure infections: 200 mg cefditoren every 12 hours for 10 days. Elderly No dose adjustments are necessary for elderly patients, except in the case of severe renal and/or hepatic function impairment. Renal insufficiency No dose adjustment is necessary for patients with mild renal impairment. In patients with moderate renal insufficiency (creatinine clearance 30-50 ml/min), the total daily dose should not exceed 200 mg cefditoren every 12 hours. In patients with severe renal insufficiency (creatinine clearance < 30 ml/min), it is recommended a single dose of 200 mg cefditoren once a day. The recommended dose has not been determined in patients undergoing dialysis (see sections 4.4 Special Warnings and Special Precautions for Use and 5.2 Pharmacokinetic Properties). Hepatic insufficiency No dose adjustments are necessary for patients with mild hepatic insufficiency (Child-Pugh A) to moderate hepatic insufficiency (Child-Pugh B). In the case of severe insufficiency (Child-Pugh C), there are no data available that would allow a recommended dose to be established (see section 5.2 Pharmacokinetic Properties). Paediatric population Spectracef is not indicated for children and adolescents under 12 years old. Method of administration Tablets should be swallowed whole with a sufficient quantity of water. Tablets should be taken with meals.
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
לא צוין
הגבלות
לא צוין
מידע נוסף